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Sumoylation is generally considered a repressive
mark for many transcription factors. However, the
in vivo importance of sumoylation for any given
substrate remains unclear and is questionable
because the extent of sumoylation appears exceed-
ingly low for most substrates. Here, we permanently
eliminated SF-1/NR5A1 sumoylation in mice
(Sf-1K119R, K194R, or 2KR) and found that Sf-12KR/2KR
mice failed to phenocopy a simple gain of SF-1 func-
tion or show elevated levels of well-established SF-1
target genes. Instead, mutant mice exhibited marked
endocrine abnormalities and changes in cell fate that
reflected an inappropriate activation of hedgehog
signaling and other potential SUMO-sensitive tar-
gets. Furthermore, unsumoylatable SF-1 mutants
activated Shh and exhibited preferential recruitment
to Shh genomic elements in cells. We conclude that
the sumoylation cycle greatly expands the functional
capacity of transcription factors such as SF-1 and is
leveraged during development to achieve cell-type-
specific gene expression in multicellular organisms.
INTRODUCTION
Many proteins involved in transcription including transcription
factors, histones, and chromatin remodeling proteins undergo
posttranslational modification by conjugation with the small
ubiquitin-like modifier (SUMO) (Gill, 2005a). The sumoylation
cycle begins with activation of SUMO by the E1 enzyme, fol-
lowed by transesterification to the E2 conjugating enzyme
(Ubc9), and ligation of SUMO to an acceptor lysine; for most
substrates this process is further stimulated by SUMOE3 ligases
(Hay, 2005). Desumoylation completes this cycle and is carried
out by Sentrin/SUMO-specific isopeptidases (SENPs). Genetic
lesions in the general sumoylation machinery show that sumoy-
lation is essential for life in both lower and higher eukaryotes.
Deleting Ubc9 in mice or its ortholog lwr in Drosophila leads toDevelopembryonic death (Apionishev et al., 2001; Nacerddine et al.,
2005), as does knocking down Ubc9 or all three Sumo paralogs
in zebrafish (Nowak and Hammerschmidt, 2006; Yuan et al.,
2010). Similarly, disrupting desumoylation in mice by removing
the SUMO-specific proteases Senp1 (Cheng et al., 2007) and
Senp2 (Kang et al., 2010) also impairs normal development.
Eliminating individual SENP proteases presumably increases
the proportion of sumoylated to unmodified substrate. This
was observed recently in Senp2/ mice, which display defects
in cardiac development resulting in part from the hypersumoyla-
tion of the repressor Pc2 and enhanced recruitment of the poly-
comb repressive complex 1 (PRC1) to Gata4 and Gata6
promoters (Kang et al., 2010). Taken together, these studies
imply that a group of critical substrates must undergo sumoyla-
tion and/or desumoylation during development.
Although these studies establish the essential requirement of
the general SUMO cycle, it remains unclear to what extent
sumoylation changes the in vivo function of a specific substrate.
To date, these questions have been partially addressed in
transgenic studies that ectopically delivered sumoylatable and
unsumoylatable substrates. For instance, SUMO fusions and
nonsumoylatable SoxE factors function differently in Xenopus
cell fate studies (Taylor and Labonne, 2005). Similarly, wild-
type and K107R PPARg exhibit different phenotypes after
adenoviral-mediated delivery in a rat carotid artery injury model
(Lim et al., 2009). Reconstitution studies also report that nonsu-
moylatable variants are far less efficient at rescuing null pheno-
types when compared with their sumoylatable counterparts.
Indeed, rescue of uterine-vulval defects with the K17,K18
LIN-11 sumoylation mutant (Broday et al., 2004), and rescue of
retinal defects with the K178R NR2E3/PNR mutant (Onishi
et al., 2009) are diminished compared with wild-type constructs.
Although these studies showed that sumoylated and unmodified
substrates function differently when ectopically delivered, the
in vivo consequences of sumoylation for an endogenously ex-
pressed substrate in a native setting remain to be determined.
Vertebrate members of the NR5A subfamily of nuclear recep-
tors, including steroidogenic factor 1 (SF-1, NR5A1) and liver
receptor homolog 1 (LRH-1, NR5A2), possess two conserved
sumoylation sites (Chen et al., 2004; Komatsu et al., 2004; Lee
et al., 2005) that are located in the large flexible hinge domainmental Cell 21, 315–327, August 16, 2011 ª2011 Elsevier Inc. 315
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SF-1 Sumoylation Specifies Endocrine Developmentjuxtaposed to either the DNA-binding domain (DBD) or the
ligand-binding domain (LBD). SF-1 is efficiently sumoylated
in vitro to nearly 100% at both Lys119 and Lys194 (Campbell
et al., 2008; Ogawa et al., 2009). As found for many transcription
factors, overexpression of unsumoylatable SF-1 increases cell-
based reporter activity and elevates ACTH-dependent steroido-
genic enzyme genes (Yang et al., 2009) without affecting protein
stability (Lee et al., 2005). Similarly, unsumoylatable LRH-1
increases reporter activity when overexpressed in cultured cells
(Chalkiadaki and Talianidis, 2005; Lee et al., 2005), and enhances
induced pluripotency when overexpressed in mouse embryonic
fibroblasts (Heng et al., 2010). Results from these cellular studies
suggest that the major effect of NR5A receptor sumoylation is
an overall repression of transcriptional activity. However, our
previous study led us to refine this notion and hypothesize that
disrupting the normal SUMO cycle of SF-1 might selectively
affect a subset of SUMO-sensitive targets rather than simply
altering SF-1 activity on all targets (Campbell et al., 2008).
To directly assess if sumoylation is essential for proper func-
tion of a single substrate in its native setting, we generated
a knockin mouse model harboring an unsumoylatable form of
SF-1 (Sf-1K119R, K194R, or 2KR). In vertebrates, SF-1 is essential
for normal endocrine tissue development and regulates genes
in the stress and reproductive endocrine-signaling axes. Hetero-
zygous Sf-1 mice exhibit moderate defects and are relatively
normal compared to the dramatic adrenal and gonadal agenesis
displayed in Sf-1/ mice (Luo et al., 1994; Bland et al., 2000).
Numerous heterozygous human SF-1 mutations are associated
with testicular dysgenesis, premature ovarian failure, andadrenal
insufficiency. Interestingly, two missense mutations associated
with male infertility map closely to K119 and K194 (Bashamboo
et al., 2010; Lourenc¸o et al., 2009). On the other hand, targeted
overexpression of SF-1 in mouse adrenals leads to adrenal
hyperplasia (Zubair et al., 2009) and results in adrenal cortical
tumors (Doghman et al., 2007). Based on these Sf-1 dosage-
sensitive phenotypes and the repressive effect of SF-1 sumoyla-
tion in cells, we asked if permanently eliminating SF-1 sumoyla-
tion would manifest as an increase in SF-1 dosage with a
concomitant elevation of well-established target genes. Here
we report that Sf-12KR/2KR mice failed to phenocopy a simple
gain (or loss) of SF-1 function but instead exhibited distinct phys-
iological abnormalities that reflected an inappropriate activation
of SF-1 targets during endocrine organ development.
RESULTS
Endocrine Tissues and Their Steroidogenic Capacity
Are Disrupted in Sf-12KR/2KR Mice
Sumoylated SF-1 is readily detected in embryonic day (E) 16.5
testes and adrenals but undetectable in the embryonic ovary,
underscoring the marked sexually dimorphic expression of SF-
1 during this early stage of gonadal development (Figures 1A
and 1D). In these embryonic tissues, the mobilities of mono-
and disumoylated SF-1 species were similar to those obtained
in cellular studies, suggesting that in vivo, SF-1 is sumoylated
at both the major (K194) and minor (K119) acceptor sites (Camp-
bell et al., 2008; Chen et al., 2004; Komatsu et al., 2004; Lee
et al., 2005; Luo et al., 2010; Ogawa et al., 2009) (Figure 1A,
and see Figure S1 available online). Given that neither K119316 Developmental Cell 21, 315–327, August 16, 2011 ª2011 Elsevienor K194 appears to be acetylated (Chen et al., 2005) or poly-
ubiquitinated (Figure S1), and to ensure that all SF-1 sumoylation
would be abolished in vivo, we chose to knock in two point muta-
tions, K119R/K194R (referred to as 2KR) in the endogenous Sf-1
mouse locus (Figures 1B and S1).
Sf-12KR/2KR mice were generated with both K119/K194 muta-
tions confirmed by PCR genotyping and genomic DNA
sequencing (Figure S1; data not shown). Unlike SF-1 null mice,
which die shortly after birth, Sf-12KR/2KR mice are viable and
show normal Mendelian ratios (data not shown). We chose to
focus initially on Sf-12KR/2KR adrenals and testes given the estab-
lished roles and prominent embryonic expression of SF-1 in
these two endocrine organs. If the Sf-12KR allele results in
a simple gain of function, then we would expect mutant mice
to exhibit elevated Sf-1 transcripts (due to autoregulation) and
adrenal hyperplasia (Doghman et al., 2007; Zubair et al., 2009).
Although Sf-12KR/2KR tissues showed a pronounced loss of
sumoylated SF-1 species, levels of mutant SF-1 transcripts
and protein were unchanged when examined at multiple devel-
opmental stages (Figures 1C, 1D, and S1). Importantly, a similar
nuclear pattern of staining was observed for SF-1 in mutant and
wild-type adrenals (Figures 1E and S1). These data demonstrate
that mutating the major and minor acceptor lysines at K119 and
K194 effectively eliminated all detectable sumoylation of SF-1
in vivo, while preserving normal SF-1 protein levels and its
subcellular localization.
Despite normal levels of SF-1 protein, Sf-12KR/2KR adult males
showed a dramatic reduction in testicular weight, degenerated
seminiferous tubules, lowered sperm count, and increased
interstitial Leydig cells (Figures 1F and S2), with all mutant
mice of both sexes eventually exhibiting infertility (Table S1).
Sf-12KR/2KR adult adrenals revealed a significant, but subtle,
decrease in weight as well (Figure 1F). Morphological differences
exhibited by mutant organs were accompanied by abnormal
hormonal output, as evidenced by elevated testicular testos-
terone and progesterone levels and a slightly lower but still
significant change in adrenal corticosterone (Figures 1G and
S2). These altered steroid profiles together with gross changes
in Sf-12KR/2KR organ morphology show that eliminating sumoyla-
tion of a specific substrate dramatically perturbs tissue organiza-
tion and function.
Cell Fate Specification Is Perturbed in Sf-12KR/2KR
Endocrine Organs
In the developing testes, SF-1 is expressed in both theSertoli and
Leydig somatic cells where it regulates genes involved in male
sexual differentiation such asMis/Amh, Sox9, and those encod-
ing steroidogenic enzymes (Parker and Schimmer, 1997; Sekido
and Lovell-Badge, 2008; Shen et al., 1994). Morphological
changes in Sf-12KR/2KR testes were apparent as early as E13.5,
as judged by irregularly branched, thin cords (Figure 2A).
Despite the marked loss of germ cells in older testes, germ cell
colonization at this early gonadal stage appeared normal with
an equivalent number of germcells found inwild-type andmutant
E13.5 testes (Figure 2A). To assess the molecular changes in
Sf-12KR/2KR endocrine organs, RNA profiling of mutant testes
and adrenals was carried out at different developmental stages
(Table S2). Surprisingly, several established adrenal markers
were misexpressed in Sf-12KR/2KR testes, as illustrated by ther Inc.
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Figure 1. Sf-12KR/2KR Mice Exhibit Disrupted Endocrine Physiology without Affecting SF-1 Protein Levels
(A) Protein lysates from Sf-1+/+ E16.5 gonads were immunoprecipitated (IP) and Western blotted (WB) using anti-SF-1 antibodies. Mono (1xSu-SF-1)- and di
(2xSu-SF-1)-sumoylated SF-1 are indicated (arrowheads) with a lighter exposure of unmodified SF-1 shown in bottom panel.
(B) The targeted allele of unsumoylatable SF-1 mutant mouse (Sf-12KR/2KR) with individual mutations shown in exon 3, and before removal of neo cassette (Neo).
(C) Sumoylation of SF-1 is abolished inSf-12KR/2KRmice. SF-1 levels are shown for postnatal day (P) 3wild-type andmutant tissueswith b-actin as loading control.
(D) Western blots of E16.5 ovaries and testes (left panels), and qPCR of E16.5 testes and adrenals (right panels) showed no difference in SF-1 protein and
transcript levels, respectively.
(E) Immunostaining of SF-1 in wild-type and mutant E16.5 adrenals.
(F) Testicular/adrenal weights and sperm counts are shown for 8- or 12-week-old wild-type and Sf-12KR/2KR males, respectively (n = 7 for Sf-1+/+ and n = 6 for
Sf-12KR/2KR).
(G) Gonadal testosterone (T) levels and adrenal corticosterone (Cort) levels measured in P23 male wild-type and Sf-12KR/2KR littermates. All data points in steroid
assays passed the Grubbs’ outliers test. See also Figures S1 and S2, and Table S1.
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SF-1 Sumoylation Specifies Endocrine Developmentprominent expression of Akr1b7 in the interstitial region of the
embryonic testes (Figures 2B and 2D). Other adrenal markers
found in mutant testes included Ly6d, Chga, and Cyp21a1
(Figure 2C).
DuringdevelopmentSF-1 isessential for adrenalmaturationand
is known to regulatemultiplegenes in the adrenal cortex. Similar to
mutant embryonic testes, E16.5 Sf-12KR/2KR adrenals misexpress
anumberof testicularmarkers (Figure3A).Perhaps themostunex-
pected embryonic marker to be misexpressed in mutant adrenals
is the well-characterized Sertoli cell marker Sox9, which is never
found in developing or adult adrenals (Figures 3A and 3B; Reiprich
et al., 2008). Sox9 misexpression is observed at E16.5 and
continues into adulthoodwithSOX9-positive cells found scatteredDevelopthroughout the adrenal cortex ofmutantmice (Figures 3B and 3C).
Interestingly, whereas both male and female mutant adrenals
misexpressed Sox9, no Sox9 could be detected in embryonic
ovaries (data not shown). Other misexpressed markers included
Amhr2, Aldh1a1, and two known targets of SOX9, Acan and
Gstm6 (Figure 3D). No ectopic SOX9 expression was observed
at an earlier stage of adrenal development (E12.5), just after sepa-
ration of adrenals from the common adrenogonadal primordia
(Figure 3E). Thus, misexpression of Sox9 at E16.5 appears to be
ectopic in nature and is unlikely to result from a migratory defect
of testicular SOX9-positive cells into the developing adrenal.
Mutant adrenals also exhibited a persistent fetal X-zone (Fig-
ure 3F). Aldo-keto reductase 1c18 (Akr1c18), which encodesmental Cell 21, 315–327, August 16, 2011 ª2011 Elsevier Inc. 317
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Figure 2. Misexpression of Adrenal Markers in Sf-12KR/2KR Testes
(A) Whole-mount in situ hybridization of Amh/Mis and immunofluorescent staining of MIS (green) and PECAM1 (red) in Sf-1+/+ and Sf-12KR/2KR E13.5 testes
showing aberrant testes cords branching without an apparent loss of germ cells.
(B) Heat map showing upregulated adrenal markers in E16.5 mutant testes compared to wild-type, with color scale bar shown.
(C) Increased expression levels of selected adrenal markers in E16.5 mutant testes.
(D) In situ hybridization and transcript levels (right) of the adrenalmarkerAkr1b7 in E16.5 wild-type andmutant testes. ST, seminiferous tubules. See also Table S2.
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SF-1 Sumoylation Specifies Endocrine Developmentthe enzyme 20a-hydroxysteroid dehydrogenase (20a-HSD),
marks the fetal adrenal zone (Hershkovitz et al., 2007) and is
elevated in adult mutant postnatal males or virgin females (Fig-
ure 3F; data not shown). Although the origin and exact function
of the murine adrenal X-zone are still mysterious, this zone is
considered a remnant of the fetal adrenal and regresses at
puberty inmales and during the first pregnancy in females (Beus-
chlein et al., 2002). That Sf-12KR/2KR mice retain this fetal tissue
implies that eliminating SF-1 sumoylation interferes with the
normal maturation of this endocrine tissue. Collectively, these
data show that SF-1 must be sumoylated for proper adrenal
and testicular cell specification.
Increased SHH Signaling and Expansion
of Steroidogenic Progenitors in Mutant Mice
Hedgehog signaling is known to play a role in the recruitment of
steroidogenic progenitors in both testes and adrenals. Testicular
Sertoli cells secrete desert hedgehog (Dhh) and promote steroid-
producing Leydig cell differentiation (Bitgood et al., 1996; Yao318 Developmental Cell 21, 315–327, August 16, 2011 ª2011 Elsevieet al., 2002). In the adrenal cortex, expression of sonic hedgehog
(Shh) rather than Dhh is needed to maintain steroidogenic
progenitors and initiate steroidogenic cell differentiation (Ching
and Vilain, 2009; Huang et al., 2010; King et al., 2009). Unexpect-
edly, Shh, which is normally undetectable in testes, is switched
on in embryonic Sf-12KR/2KR testes (Figures 4A, 4B, and S3).
Beginning at E13.5, strong Shh expression is observed in the
interstitial compartment of Sf-12KR/2KR testes, but not in wild-
type littermates (Figure 4C). In contrast, Dhh expression is
decreased in mutant testes (Figure S3). Further analyses
confirmed that Shh- and GLI1-positive cells were markedly
elevated in E16.5 mutant testes (Figures 4C and 4D) along with
downstream effectors of hedgehog signaling such as Gli1,
Ptch1, and Hhip (Figure 4A).
Shh expression in embryonic adrenals is always restricted to
the immediate subcapsular layer. However, in Sf-12KR/2KR adre-
nals this restricted pattern is expanded, penetrating deep into
cortical layers (Figure 4C). More important, and consistent with
an increase in SHH protein, hedgehog signaling is greatlyr Inc.
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Figure 3. Misexpression of Testicular Markers Such as SOX9, and Retention of the Fetal X-Zone in Sf-12KR/2KR Adrenals
(A) Heat map showing upregulated testicular markers in E16.5 mutant adrenals compared to wild-type.
(B) Elevated expression of the testis-specific marker Sox9 in E16.5 and P28 mutant male adrenals.
(C) SOX9 staining in E16.5 male adrenals (green) in wild-type or mutant adrenals (higher magnification shown in insets).
(D) Expression of testicular markers and Sox9 target genes in E16.5 wild-type and mutant adrenals.
(E) Transverse sections of E12.5 embryos were stained for SF-1 (green) to locate adrenals (A) and testes (T), as indicated by dashed circles. SOX9 (red) signal is
absent in adrenals in both wild-type and Sf-12KR/2KR embryos.
(F) Representative photomicrographs of H&E and immunohistochemical staining of 20a-HSD (AKR1C18) in 8-week-old male adrenals show cortical hypoplasia
and persistence of the fetal X-zone as indicated by AKR1C18 staining (right, arrowheads). X-zone infiltration into adrenal medulla is indicated with arrows. DZ,
definitive zone; M, adrenal medulla; X, X-zone. See Table S2.
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SF-1 Sumoylation Specifies Endocrine Developmentenhanced in mutant adrenals, as demonstrated by the notable
expansion of GLI1-positive cells in the subcapsular layer and
definitive zone (Figure 4D). In older adrenals, these scattered
Gli1-positive cells persist and are distributed throughout the
cortex (Figure 4D). Thus, in both mutant adrenals and testes,
loss of SF-1 sumoylation either elevates or ectopically activates
Shh expression to amplify hedgehog signaling. In this regard, the
altered steroid profiles observed in mutant adrenals was partially
restored by reducing Shh gene dosage in Sf-12KR/2KR animals
(Figure 4E).DevelopEliminating SF-1 sumoylation in the embryonic testes resulted
in grossmorphological and transcriptional changes that reflected
increased Leydig cell function (Figures 5A and 5C). This change
was met with a corresponding decrease in Sertoli cell function,
as judged by the loss of Sertoli cell markers, such as SOX9
(Figures 5B, 5C, 5E, and S3; Abel et al., 2009). Expansion of fully
differentiated Leydig cells begins early in E16.5mutant testes, as
judged by the increased 3b-HSD expression and staining, aswell
as the significantly elevated levels of testosterone (Figures 5D,
5F, and 5G). The presence of scattered SOX9-positive cells inmental Cell 21, 315–327, August 16, 2011 ª2011 Elsevier Inc. 319
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Figure 4. SHH Signaling Is Amplified in Sf-12KR/2KR Adrenals and Ectopically Activated in Sf-12KR/2KR Testes
(A) Expression of Shh and signaling targets in E16.5 testes.
(B) Increased SHH protein levels in E16.5 mutant endocrine tissues.
(C) Ectopic expression of Shh in embryonic mutant testes at E13.5 by whole-mount ISH and at E16.5 by section ISH. Embryonic mutant adrenals also showed
increased cortical Shh expression at E16.5 by section ISH. Arrows indicate Shh-positive interstitial cells with seminiferous tubules indicated (ST, dotted circles).
(D) GLI1-positive cells in Sf-12KR/2KR tissues were visualized by crossingSf-12KR/2KRmice to theGli1LacZ (Gli1tm2Alj) reporter line. X-gal staining revealed increased
GLI1-positive cells in Sf-12KR/2KR E16.5 testes and an altered, more intense pattern of GLI1-positive cells in mutant E16.5 or 8-week adrenals.
(E) Adrenal aldosterone measured from Sf-1+/+, Sf-12KR/2KR, and Shh+/; Sf-12KR/2KR P23 males showed partial rescue of hormone deficits by lowering Shh gene
dosage. See Figure S3.
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SF-1 Sumoylation Specifies Endocrine Developmentthe interstitial region and the aberrant staining pattern of the peri-
tubular myoid cell marker, a smooth muscle actin, suggested
strongly that the integrity of the seminiferous tubules was
severely compromised inmutant testes (Figures 5HandS3;Clark
et al., 2000). These data show that disrupting the normal SUMO
cycle of SF-1 not only increased SHH signaling but also impaired
normal endocrine organ development by expanding or contract-
ing specialized cell types.
SF-1 Unsumoylatable Mutant Protein Directly Regulates
Shh Expression
We next asked whether misexpression of SUMO-sensitive
genes such as Shh observed in mutant mice is a direct conse-
quence of loss of SF-1 sumoylation. Initially, inducible cell lines
that express a panel of unsumoylatable SF-1 variants were
generated in HEK293 cells (Figures 6A and S4). In addition to
the 2KR mutant, individual lysine mutants (K119R and K194R),320 Developmental Cell 21, 315–327, August 16, 2011 ª2011 Elsevieas well as an SF-1 SUMO consensus site mutant E121A/
E196A (2EA), were also included in this panel. By disrupting
the UBC9 substrate recognition sequence, the E to A mutation
prevents sumoylation but leaves the acceptor lysines available
for alternative modifications, including acetylation and ubiquiti-
nation (Sampson et al., 2001). As expected, neither the 2KR
nor 2EA SF-1 proteins are sumoylated (Figure 6A). In HEK293
cells, wewere able to directly compare the transcriptional effects
of all SF-1 variants when expressed at equivalent protein levels.
Profiling of these stable cell lines showed that direct SF-1 targets
such as CYP17A1, G0S2, and MEOX1 (Whitby et al., 2011) are
induced equally by wild-type and all SF-1 SUMO mutants
(Figures 6A and S4), while some well-established targets such
as StAR and CYP11A1 trended slightly higher (data not shown),
consistent with results fromHammer and colleagues (Yang et al.,
2009). However, similar to what was found in Sf-12KR/2KR tissues,
several distinct targets including DLL-1, NEFH, and ADRA2Ar Inc.
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Figure 5. Steroidogenic Leydig Cells Are Expanded in Sf-12KR/2KR Mutant Testes
(A and B) Heat maps showing relative levels (fold over wild-type) of Leydig cell markers (A) and Sertoli cell markers (B) in Sf-12KR/2KRmutant testes and adrenals.
(C) qPCR showed increased expression of Leydig cell markers with a corresponding decrease in Sertoli cell markers in E16.5 Sf-12KR/2KR mutant testes.
(D and E) Western blots of 3b-HSD (D), and SOX9 (E) in E16.5 gonads or testes with b-actin as loading control.
(F) SF-1 (green) and 3b-HSD (red, marking Leydig cells) staining in E16.5 testes with higher magnification showing nuclear SF-1 and cytoplasmic 3b-HSD staining
in mutant interstitial Leydig cells (inset).
(G) Testosterone levels in mutant and wild-type P0 testes.
(H) Immunofluorescent staining of the peritubular myoid cell marker a smooth muscle actin (a-SMA) exhibited an abnormal staining pattern in 4-week-old mutant
testes (arrows). See Figure S3.
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SF-1 Sumoylation Specifies Endocrine Developmentwere induced by both the 2KR and 2EA variants, but not by wild-
type SF-1 (Figures 6A and S4). Interestingly, full activation of
these SUMO-sensitive targets varied among different SUMO
mutants. For example, activation of some genes (DLL-1 and
ADRA2A) was nearly equivalent for the single K194R and 2KR
and 2EA double mutants. For other genes (NEFH), full activation
was only observedwith the doublemutants (Figure S4). Although
it remains to be determined how each mutant activates this
subset of SUMO-sensitive targets, our data confirm that for
most targets, the 2KR and 2EA SF-1 variants are functionally
similar.DevelopTo determine if the 2KR and 2EA variants directly activate SHH
signaling, as observed in Sf-12KR/2KR mice, we used an embry-
onic cell line (mHypoE-40) that is highly responsive to exogenous
SF-1. Stable mHypoE-40 cell lines were generated with equal
WT or 2EA protein levels (Figure 6B); 2KR lines were also created
but consistently expressed far less protein (Figure S4). As
observed with Sf-12KR/2KR, eliminating sumoylation in the 2EA
(and K119R) variant increased Shh and activated SHH signaling,
as judged by elevated SHH protein and an increase in the
hedgehog target gene Gli1 (Figures 6B and S4). Shh was also
induced in the 2KR SF-1 mHypoE-40 cells despite reducedmental Cell 21, 315–327, August 16, 2011 ª2011 Elsevier Inc. 321
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Figure 6. Unsumoylatable SF-1 Directly Regulates a Subset of SUMO-Sensitive Target Genes
(A) Levels of unmodified and sumoylated (arrowheads) 3xFLAG-tagged WT and unsumoylatable 2EA and 2KR SF-1 variants in HEK293 cells after 24 hr tetra-
cycline (Tet) induction. SUMO consensus sequence and mutations (underlined) are listed. Graphs represent relative expression of the SUMO-sensitive targets
(DLL-1, NEFH, and ADRA2A, top), and SUMO-insensitive targets (CYP17A1, G0S2, and MEOX1, bottom) following 24 hr Tet-induced SF-1 expression. Bars
indicate fold over vehicle control (+SD).
(B) Protein inmHypoE-40 stable cells was detectedwith anti-FLAG, anti-SHH, or anti-b-actin antibodies. Relative expression ofShh and SHH targetGli1 (top) was
increased after induction of 2EA SF-1 proteins compared to equivalent induction of Cyp11A1 and Vnn1.
(C) EMSAs of unsumoylated SF-1 binding to either a noncanonical site found in the Shh promoter or to the canonical Cyp11a1 site (left). Input of in vitro
sumoylated SF-1 DBD protein for each reaction is shown below EMSAs. In the absence of the major K119 acceptor lysine, cryptic sumoylation of SF-1 is
observed at either K100 or K106, as indicated by *.
(D) ChIP-qPCR results showing relative fold recruitment with all values normalized to empty vector (EV) control in mHypoE-40 stable cell lines; forward and
reverse primers are provided in Supplemental Experimental Procedures.
(E) Relative levels of Shh expression after overexpressing Senp1 plasmid in mHypoE-40 cells stably expressing WT SF-1 (top) or 2EA (bottom), with each
compared to the EV control. Experiments have been performed at least three times. See also Figure S4.
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SF-1 Sumoylation Specifies Endocrine DevelopmentSF-1 protein levels (Figure S4). In contrast, well-characterized
SF-1 targets Vnn1 and Cyp11a1 were largely unaffected by the
sumoylation status of SF-1 (Figures 6B and S4). These cellular
data support our hypothesis that loss of SF-1 sumoylation in
Sf-12KR/2KR tissues leads to inappropriate activation of SUMO-
sensitive genes in select cell types.
Previously, we reported that when the minor site at K119 is
sumoylated, recognition by SF-1-DBD of nonconsensus binding322 Developmental Cell 21, 315–327, August 16, 2011 ª2011 Elseviesites is diminished (Campbell et al., 2008). Given that Shh is also
induced in K119R stable mHypoE-40 cells (Figure S4), we asked
if SF-1 binding to Shh upstream genomic regions correlated
with the sumoylation status of SF-1. In vitro sumoylated SF-1
protein containing the DBD and hinge region that includes
K119, but not K194 (SF-1-DBD), binds poorly to a putative
SF-1 nonconsensus binding site in the Shh regulatory region
but binds well to the high-affinity Cyp11a1 canonical siter Inc.
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Figure 7. Unsumoylatable SF-1 Prevails over the
Wild-Type SF-1 and Ectopically Activates SUMO-
Sensitive Genes In Vivo
(A) Shh and Sox9 transcript levels are shown for E16.5
testes and adult male adrenals, respectively. Statistical
significance was determined by one-way ANOVA.
(B) Comparison of adult adrenals obtained from different
allelic combinations as indicated, by either tyrosine
hydroxylase staining of adrenal medulla (green), or
AKR1C18/20a-HSD staining, whichmarks cells of the fetal
X-zone (brown, black arrows). The eccentric smaller
medulla observed in heterozygous Sf-1+/ adrenal is
further exaggerated in Sf-12KR/ adrenals.
Developmental Cell
SF-1 Sumoylation Specifies Endocrine Development(Figure 6C; Campbell et al., 2008). When sumoylation is elimi-
nated at K119, binding to the Shh site is restored (Figure 6C,
K119A DBD, far-right lanes). Consistent with the gel shift data,
only the SF-1 2EA mutant protein is recruited to the noncanon-
ical site upstream of the Shh gene in a chromatin immunopre-
cipitation (ChIP)-qPCR assay (Figures 6D and S4). Unfortu-
nately, the much lower expression of the SF-1 2KR mutant in
stable mHypoE-40 cells precluded a similar ChIP analysis (Fig-
ure S4). Overexpressing the SUMO-isopeptidase Senp1 in
mHypoE-40 cells provides further proof that unsumoylatable
SF-1 selectively activates Shh. Indeed, a Senp1 dose-depen-
dent increase in endogenous Shh was observed with wild-
type SF-1 but not with SF-1 SUMO mutant cells, including
2KR, 2EA, and K119R (Figures 6E and S4). We infer from these
data that sumoylation modulates DNA-binding specificity of
SF-1 and that SUMO-sensitive targets, such as Shh, can be
activated once SF-1 is desumoylated.
The Sf-12KR Unsumoylatable Allele Is Dominant
Ectopic expression of Shh, Sox9, and AKR1C18 in mutant
endocrine organs was used to determine if the Sf-12KR allele is
dominant or recessive. In all cases, we found a clear andmarked
increase in the expression of these SUMO-sensitive markers
in Sf-12KR/+ heterozygous tissues. Both Shh and Sox9 areDevelopmental Cell 21, 3ectopically activated in Sf-12KR/+ heterozygous
and Sf-12KR/ hemizygous testes or adrenals,
respectively (Figure 7A). For Shh, the presence
of one wild-type allele in Sf-12KR/+ testes re-
sulted in less ectopic activation compared to
hemizygous Sf-12KR/ testes, suggesting that
the sumoylatable allele can partially oppose
the dominant effects of the Sf-12KR mutant
allele. The presence of 20a-HSD (AKR1C18)-
positive cells infiltrating the adrenal medulla
and the persistent fetal X-zone in Sf-12KR/+
heterozygous adrenals also illustrates the
dominance of the Sf-12KR allele (Figure 7B).
Pronounced differences in adrenal morphology
were also observed between Sf-1+/ and
Sf-12KR/ genotypes, underscoring the func-
tional differences between the wild-type and un-
sumoylatable alleles (Figure 7B). These genetic
data provide further proof that the Sf-12KR alleleis functionally distinct from the wild-type allele and dominates to
potently activate SUMO-sensitive genes such as Shh.
DISCUSSION
Here, we report that loss of substrate-specific sumoylation in
a multicellular organism causes profound changes in cell fate
specification, organogenesis, and normal physiology. The ability
to permanently alter the endogenous ratio of sumoylated to
unmodified SF-1 protein by knocking in the mutant Sf-12KR allele
allowed us to clarify the full in vivo function of substrate-specific
sumoylation. Unlike other studies aimed at disrupting the
sumoylation cycle (Cheng et al., 2007; Kang et al., 2010; Nacerd-
dine et al., 2005), this report shows that establishing and main-
taining SUMO modification on a specific substrate is critical for
orchestrating complex gene expression patterns. Specifically,
we find that mice harboring only the nonsumoylatable variant
of the nuclear receptor SF-1 exhibit marked changes in endo-
crine tissue development and function. Although most cellular
data suggest that sumoylation simply represses or shuts off tran-
scriptional activity, our in vivo data show that the sumoylation
cycle of a substrate functions instead to ensure appropriate
gene expression during development. Thus, rather than simply
activating all SF-1 targets, a distinct subset of SF-1 targets15–327, August 16, 2011 ª2011 Elsevier Inc. 323
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Figure 8. Sumoylation of SF-1 Is Critical for Normal
Endocrine Tissue Development
A schematic summarizing our results showing that shifting
the normal ratio of sumoylated to unsumoylated SF-1 to
only unmodified SF-1 (bottom left) in Sf-12KR/2KR mice
interferes with normal endocrine tissue development and
results in the ectopic expression of SUMO-sensitive SF-1
target genes, such as Shh (dark blue), Sox9 (red), and
Akr1c18, which marks the fetal X-zone (brown ring in
adrenal). We hypothesize that the correct ratio of sumoy-
lated to unmodified substrate is needed to selectively turn
on/off developmental gene programs (right). Transcrip-
tional coactivators (CoA) and/or corepressors (CoR) might
also be involved in this process.
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SF-1 Sumoylation Specifies Endocrine Developmentwas activated in mutant Sf-12KR/2KR mice, which correlated well
with the cellular and morphological changes observed in mutant
endocrine organs, as depicted in Figure 8.
Our data suggest that disrupting SF-1 sumoylation affects
expression of endocrine organ-specific markers as evidenced
by expression of classic adrenal markers in mutant testes
(Akr1b7 and Cyp21a1) and the surprising expression of the
testicular marker Sox9 and its downstream targets (Acan,
Gstm6, Gdf5, and Aldh1a1) in mutant adrenals. The appearance
of inappropriate markers in mutant tissues might reflect an
under-differentiated cell population possessing intermediate
steroidogenic cell fates as shown by others (Bernichtein et al.,
2008; O’Shaughnessy et al., 2003; Val et al., 2006). However,
we find no evidence for subpopulations of interstitial cells in
mutant testes and have yet to identify a marker that colocalizes
with SOX9 in mutant adrenals. The dramatic changes in cell fate
markers observed in Sf-12KR/2KR mice are similar to transcrip-
tional changes observed after overexpressing either unmodified
NR2E3 in embryonic retinal tissue or a Sox9-SUMO fusion in
Xenopus embryos (Onishi et al., 2009; Taylor and Labonne,
2005). Together with our knockin study, we conclude that su-
moylation provides additional regulatory capacity and greatly
enhances the functional diversity of transcriptional factors to
orchestrate proper gene expression (Gill, 2005b).
We find that ectopic or expanded SHH signaling correlates
well with the increase in interstitial Leydig-like cells, elevated
steroid hormone production, and disturbed adrenal zonation in
mutant mice. These data are consistent with known roles of
hedgehog signaling in promoting gonadal steroidogenesis (Bar-
soum et al., 2009; Bitgood et al., 1996) and in maintaining
steroidogenic lineages in mouse adrenals (Ching and Vilain,
2009; Huang et al., 2010; King et al., 2009). In Sf-12KR/2KR embry-
onic adrenals, Shh- and GLI1-positive cells increase and expand
well beyond the subcapsular region. Similar changes are
observed for Cyp17a1-positive cells (data not shown), suggest-
ing that SF-1 sumoylation normally restricts expression of both
Shh and Cyp17a1 to the immediate subcapsular zone. Paradox-
ically, older mutant adrenals eventually shrink with age and
exhibit reduced Shh (data not shown) and a noticeably thinner
subcapsular layer of GLI1-positive cells. This apparent reduction
in adrenal stem cells is consistent with increased cortical thin-
ning and reduced adrenal weights in older mice. We propose324 Developmental Cell 21, 315–327, August 16, 2011 ª2011 Elseviethat the early expansion of Shh-positive adrenal progenitors in
Sf-12KR/2KR mice might ultimately disrupt steroidogenic cell
differentiation by recruiting progenitors prematurely or inter-
fering with the stem cell niche. In support of this hypothesis,
reducing Shh gene dosage in Sf-12KR/2KR animals partially
restored the hormone deficit observed in mutant adrenals. Still
unknown is how changes in pituitary and/or hypothalamic endo-
crine signaling impinge on adrenal physiology in Sf-12KR/2KR
mice, and how other targets activated by unsumoylatable SF-1
contribute to mutant phenotypes.
Our study provides compelling evidence that unmodified and
sumoylated substrates function differently, with both variants
presumably needed to regulate the full spectrum of SF-1
dosage-sensitive and SUMO-sensitive targets. The pronounced
differences observed between Sf-1+/ and Sf-12KR/ genotypes
in adrenal morphology and testicular Shh expression establish
that the wild-type and 2KR alleles are distinct. Moreover, the
Sf-12KR allele is clearly dominant over the wild-type allele as
evidenced by elevated Shh and Sox9 in Sf-12KR/+ tissues. We
therefore infer that the correct ratio of sumoylated to unmodified
SF-1 must be maintained for proper development. Additionally,
disturbing this ratio for SF-1 or other receptors sharing similar
DNA recognition, such as LRH-1, could inappropriately activate
SHH signaling; this scenario might be particularly relevant to
certain types of cancer such as pancreatic adenocarcinomas
(Morton et al., 2007; Petersen et al., 2010).
The unexpected ectopic induction of SHH signaling in
Sf-12KR/2KR embryonic endocrine tissues and in a cellular model
system strongly supports the idea that Shh is extremely sensitive
to the sumoylation status of SF-1. Although sumoylation appears
to be the predominant modification on K119 and K194, it is
possible that mutating these lysines disrupts other modifications
and contributes to phenotypes observed in Sf-12KR/2KR mice. In
this regard, although mHypoE-40 cellular data suggest that 2KR
behaves slightly differently than the 2EA variant (which blocks
UBC9 recruitment), both variants also activated Shh in these
cells and appeared to be virtually identical in HEK293 cells.
Further examination of these two unsumoylatable variants in
different cellular contexts should help resolve their subtle func-
tional differences noted in our cellular studies, and might also
reveal sumoylation-independent roles for UBC9 as recently
described (Suda et al., 2011).r Inc.
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SF-1 Sumoylation Specifies Endocrine DevelopmentProfiling endocrine tissues and cells expressing only unsu-
moylatable SF-1 identified scores of SUMO-sensitive targets.
The precise mechanisms underlying the transcriptional and
phenotypic changes inmutant mice and cells remain to be deter-
mined. Unsumoylatable SF-1 might displace transcriptional
repressors sharing the same DNA-binding specificity or instead
alter recruitment of corepressors such as ARIP4 (Ogawa et al.,
2009), or transcriptional activators. In this regard, no changes
in Co-REST or NCoR recruitment on SUMO-sensitive promoters
were identified by ChIP analyses (data not shown). Ligand-
dependent sumoylation of other nuclear receptors such as
PPARg, LXR, and LRH-1 is proposed to maintain a repressor
complex and inhibit gene expression in the inflammatory and
hepatic acute phase responses (Ghisletti et al., 2007; Pascual
et al., 2005; Venteclef et al., 2010). Similarly, derepression of
tissue-specific genes accompanied by reduced recruitment of
repressive chromatin-modifying enzymes was noted in Sp3
sumoylation-deficient MEFs (Stielow et al., 2010). These models
of SUMO-dependent repression explain nicely how an exceed-
ingly small amount of sumoylated receptor exerts a potent
dominant effect. However, for most SUMO-sensitive targets
identified here, the unsumoylatable Sf-12KR allele is dominant.
In other words, the unsumoylatable SF-1 allele prevails even in
the presence of wild-type SF-1. Moreover, in mHypoE-40 cells,
Shh is induced strongly only after expressing the mutant SF-1
variants or with wild-type SF-1 in combination with SENP1.
Thus, in addition to SUMO-dependent repression, our data
suggest that during developmental stages substrate desumoyla-
tion is also used to activate SUMO-sensitive genes. Future
comprehensive genomic analysis of these highly SUMO-sensi-
tive genes may reveal a common motif or cofactor that functions
similarly to the proposed synergy control model (In˜iguez-Lluhı´
and Pearce, 2000).
The fact that SF-1 is efficiently sumoylated in vitro but appears
to be inefficiently sumoylated in endocrine tissues or cells (this
study; Lee et al., 2005) underscores the perplexing discrepancy
between the ability to detect sumoylated substrates and the
functional importance of general sumoylation. This so-called
‘‘SUMO enigma’’ (Hay, 2005) might simply reflect a highly
dynamic cycle of modification coupled with suboptimal methods
for detecting sumoylation. In this regard we find that the slightest
manipulation of endocrine tissues completely abrogates detec-
tion of sumoylated-SF-1. On the other hand, and as previously
proposed, sumoylation might be transient but impose a perma-
nent imprinted functional mark on a substrate, such as SF-1, or
on chromatin components (Shiio and Eisenman, 2003) that
regulate expression of SUMO-sensitive genes. Despite this
lingering dilemma, we demonstrate that SUMO modification of
transcription factors such as SF-1 is important in vivo and
provides an essential, added layer of regulation for fine-tuning
temporal and spatial gene expression in mammalian organ
development.EXPERIMENTAL PROCEDURES
Generation of 2KR Knockin Mice
ThemouseSf-1 (Nr5a1) BAC clone 21761 (GenomeSystems, Inc.) was used to
create the targeting construct, as shown in Figure S1. Site-directed mutagen-
esis was carried out to create the K119R/K194R mutations and introduce XhoIDevelopand BglII sites into the PCR-amplified fragment corresponding to Chr2:
38,566,194-38,560,555 (based on NCBI m37 mouse assembly) containing
exon 3. The full targeting construct was sequenced and contained a floxed
IRES-neo cassette inserted into intron 3 and the diphtheria toxin A (DT-A)
cassette inserted into the 30 targeting vector arm. Embryonic stem cell target-
ing and generation of chimera mice were performed by the Transgenic Animal
Model Core at University of Michigan. Southern blotting confirmed the pres-
ence of the XhoI and BglII sites in one clone out of 500 screened. Routine
genotyping of mutant animals was carried out using primer IE3 (forward
primer, 50-CACAGCTGTGCGTGCTGATC-30, and reverse primer, 50-GGTAC
CCACCTCCAGCTCCTT-30) to amplify exon 3, followed by restriction digestion
using either XhoI or BglII. Mice were kept on a 12 hr light/dark cycle. Hetero-
zygous SHH mutant mice (Shhtm1Amc) were bred with Sf-12KR/+ heterozygous
mice to generate Sf-12KR/2KR; Shh+/mice. All research with animals was per-
formed according to guidelines approved by the UCSF IACUC.
Cell Lines and Transfections
Murine immortalized hypothalamic mHypoE-40 cells were generated from E17
mouse hypothalami obtained from BALB/c females and DC1 males (Charles
River Laboratories) and dissected individually, dispersed through trituration,
and plated as primary culture. Cultures were immortalized with recombinant
murine retrovirus harboring simian virus (SV40) T-antigen and the neomycin
resistance gene from the pZIP-Neo SV(X)1 vector, as previously described
(Mayer et al., 2009). Immortalized neurons were selected by geneticin (G418).
The clonal mHypoE-40 cell line was analyzed for the expression of specific
markers by semiquantitative reverse transcriptase-PCR (see http://www.
cellutionsbiosystems.com/). The Flp-In T-REx system was introduced into
mHypoE-40 cells cultured in DMEM (Invitrogen), 10% Tetracycline-screened
FBS (Hyclone), and 1% pen-strep and selected with 250 mg/ml Zeocin and
5 mg/ml Blasticidin (Invitrogen). Stable cell lines expressing 3xFLAG-tagged
WT, 2EA, 2KR, K119R, K194R, and empty vector (pcDNA5-frt/TO) were
created in the Flp-In T-REx HEK293 and mHypoE-40 cell lines and selected
with 100 or 150 mg/ml Hygromycin, respectively (Campbell et al., 2008). For
the 2EAmutant, Glu121 and Glu196 were changed to Ala by PCRmutagenesis
(Stratagene). mHypoE-40 empty vector or 3xFLAG-WT SF-1 stable cells were
transfected with pCI-Neo or pCI-Neo-mSENP1 using TransIT-2020 reagent
(Mirus). Six hours after transfection, cells were treated with tetracycline
(Teknova), and total RNAs were harvested 72 hr posttransfection.
Microarrays
Mouse Exonic Evidence Based Open-source (MEEBO) arrays were printed at
the Center for Advanced Technology (CAT) at University of California, San
Francisco (UCSF). Hybridizations were carried out as described (Kurrasch
et al., 2007) using total RNA isolated from E16.5 adrenal (8.5 mg), E16.5 testes
(10 mg), and P28 adrenal or testes (10 mg). All hybridizations were performed at
65C for 16 hr usingMAUI hybridization chambermixers with theMAUI hybrid-
ization systems (BioMicro Systems). Arrays were scanned using an Axon
Scanner 4000B, and data were analyzed by GenePix 6.0 software (Molecular
Devices). Heat maps were generated using Cluster 3 and TreeView (http://
bonsai.hgc.jp/mdehoon/software/cluster).
SF-1 In Vitro Sumoylation and Electrophoretic Mobility Shift Assays
In vitro sumoylation of SF-1 DBD fragment was described previously (Camp-
bell et al., 2008) and carried out in 50 ml reactions with 1 mM SF-1-DBD,
0.12 mM E1, 4 mM UBC9, and 10 mM SUMO-1 in buffer containing 50 mM
Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM MgCl2, 2 mM ATP, and 2 mM DTT at
37C for 1.5 hr. Electrophoretic mobility shift assays (EMSAs) were carried
out with sumoylated SF-1 DBD, 2 mM DTT, 10 mM double-stranded oligonu-
cleotides, with or without 3 U of Ulp1 protease (LifeSensors), and incubated
at room temperature for 30 min. Each reaction was then resolved by 7.5%
SDS-PAGE and by 6% native PAGE in 1 3 TBE buffer at 4C. DNA-protein
complexes were detected using the fluorescence-based EMSA kit (Molecular
Probes) and a Typhoon scanner. EMSA primers are as follows: hCYP11A1,
forward 50-ACATTTTATCAGCTTCTGGTATGGCCTTGAGCTGGTAGTTATAA
TCTTGGC-30 and reverse 50-GCCAAGATTATAACTACCAGCTCAAGGCCAT
ACCAGAAGCT-GATAAAATGT-30; mShh BS1, forward 50-ACGCCATCTAGC
GGCAGGGCCAGAA-GGGGGAAG-30 and reverse 50-CTTCCCCCTTCTGG
CCCTGCCGCTAGATGGCGT-30.mental Cell 21, 315–327, August 16, 2011 ª2011 Elsevier Inc. 325
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Data are represented as mean + SEM (or SD, as indicated): *p < 0.05;
**p < 0.005; ***p < 0.001. Statistical analyses were performed using Prism 5
(GraphPad) software. Unless otherwise indicated, statistical significance
was determined by Student’s t test.
See Supplemental Experimental Procedures for additional experimental
procedures.
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